{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:53:32Z","timestamp":1776041612218,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018601","name":"Wales Cancer Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clon.2025.103963","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T23:01:25Z","timestamp":1761433285000},"page":"103963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9430-8214","authenticated-orcid":false,"given":"K.","family":"Datta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-1496","authenticated-orcid":false,"given":"A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-5152","authenticated-orcid":false,"given":"D.","family":"Holland-Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2025.103963_bib1","series-title":"Implementing a timed oesophago-gastric cancer diagnostic pathway.","year":"2023"},{"key":"10.1016\/j.clon.2025.103963_bib2","series-title":"State of the Nation Report 2025","year":"2025"},{"key":"10.1016\/j.clon.2025.103963_bib3","series-title":"Cancer Survival in England, cancers diagnosed 2016 to 2020, followed up to 2021.","year":"2023"},{"key":"10.1016\/j.clon.2025.103963_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25310","article-title":"Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT","volume":"25","author":"Adamson","year":"2021","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clon.2025.103963_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102289","article-title":"Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature","volume":"100","author":"de la Fouchardiere","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2025.103963_bib6","first-page":"362","article-title":"Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA: A Cancer J Clinicians"},{"key":"10.1016\/j.clon.2025.103963_bib7","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/jgs.13819","article-title":"The Prognostic Importance of Frailty in Cancer Survivors","volume":"63","author":"Brown","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clon.2025.103963_bib8","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib9","series-title":"National oesophago-gastric cancer audit 2021: an audit of the care received by people with oesophago-gastric cancer in England and Wales","author":"Park","year":"2021"},{"key":"10.1016\/j.clon.2025.103963_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00001","article-title":"Decision Support Systems in Oncology","volume":"3","author":"Walsh","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clon.2025.103963_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4961768","article-title":"Decision Support Systems in Prostate Cancer Treatment: An Overview","volume":"2019","author":"van Wijk","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clon.2025.103963_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(22)00391-6","article-title":"A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study","volume":"23","author":"Kleppe","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib13","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2018.07.136","article-title":"Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology","volume":"103","author":"Cabarrou","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib15","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib16","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12961-019-0504-4","article-title":"Palliative Care Evidence Review Service (PaCERS): a knowledge transfer partnership","volume":"17","author":"Mann","year":"2019","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.clon.2025.103963_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.clon.2025.103963_bib19","series-title":"CASP RCT checklist","year":"2022"},{"key":"10.1016\/j.clon.2025.103963_bib20","series-title":"CASP cohort study checklist","year":"2022"},{"key":"10.1016\/j.clon.2025.103963_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLOS Med"},{"key":"10.1016\/j.clon.2025.103963_bib22","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.3748\/wjg.v21.i16.4911","article-title":"Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg","volume":"21","author":"Berger","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clon.2025.103963_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10051079","article-title":"Role of baseline computed-tomography-evaluated body composition in predicting outcome and toxicity from first-line therapy in advanced gastric cancer patients","volume":"10","author":"Catanese","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clon.2025.103963_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jcsm.12371","article-title":"Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy","volume":"10","author":"Dijksterhuis","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clon.2025.103963_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006724","article-title":"A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer","volume":"5","author":"Groene","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2025.103963_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cam4.638","article-title":"Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy","volume":"5","author":"Kou","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clon.2025.103963_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221123617","article-title":"Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study","volume":"16","author":"Liao","year":"2022","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12957-021-02283-6","article-title":"Impact of skeletal muscle mass in patients with recurrent gastric cancer","volume":"19","author":"Matsunaga","year":"2021","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1186\/s12885-021-08953-8","article-title":"Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil","volume":"21","author":"Matsunaga","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib31","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.21873\/anticanres.16704","article-title":"Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer","volume":"43","author":"Matsunaga","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2025.103963_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00595-023-02721-w","article-title":"Prognostic significance of the cachexia index in patients with unresectable advanced gastric cancer receiving palliative chemotherapy: a retrospective single-center study","volume":"54","author":"Matsunaga","year":"2024","journal-title":"Surg Today"},{"key":"10.1016\/j.clon.2025.103963_bib33","article-title":"Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?","author":"Mohring","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jgo.2021.12.009","article-title":"Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the GO2 trial","volume":"13","author":"Pearce","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ajco.13025","article-title":"Metastatic gastric cancer: Does the site of metastasis make a difference? Asia","volume":"15","author":"Tan","year":"2019","journal-title":"Pac J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/bjc.2016.442","article-title":"A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)","volume":"116","author":"Hall","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6186543","article-title":"Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies","volume":"2016","author":"Kelly","year":"2016","journal-title":"J Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric Assessment\u2013Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib39","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What Is Value in Health Care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2025.103963_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.29773","volume":"122","author":"Kaymakcalan","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib41","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jgs.16372","article-title":"Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium","volume":"68","author":"Bhasin","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clon.2025.103963_bib42","first-page":"15","article-title":"Cachexia versus sarcopenia","volume":"14","author":"Rolland","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.clon.2025.103963_bib43","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-021-09103-w","article-title":"Metastatic gastroesophageal cancer in older patients \u2013 is this patient cohort represented in clinical trials?","volume":"22","author":"Hennessy","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2025.103963_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/ph14020151","article-title":"Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma","volume":"14","author":"H\u00f6gner","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.clon.2025.103963_bib46","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib47","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2025.103963_bib48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.clon.2025.103963_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/OP.2023.19.11_suppl.245","article-title":"Effect of immunotherapy on health-related quality of life outcomes in patients with advanced gastro-esophageal cancers: A meta-analysis","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clon.2025.103963_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177797","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis","volume":"1002","author":"Ibrahim","year":"2025","journal-title":"Eur J Pharmacol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:26:11Z","timestamp":1776039971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"alternative-id":["S0936655525002183"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103963","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103963"}}